[go: up one dir, main page]

AR088413A1 - INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7 - Google Patents

INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7

Info

Publication number
AR088413A1
AR088413A1 ARP120100896A ARP120100896A AR088413A1 AR 088413 A1 AR088413 A1 AR 088413A1 AR P120100896 A ARP120100896 A AR P120100896A AR P120100896 A ARP120100896 A AR P120100896A AR 088413 A1 AR088413 A1 AR 088413A1
Authority
AR
Argentina
Prior art keywords
amino acid
residue
acid residue
basic
secys
Prior art date
Application number
ARP120100896A
Other languages
English (en)
Inventor
K Murray Justin
P Miranda Leslie
I Mdonough Stefan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR088413A1 publication Critical patent/AR088413A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe una composición, la cual comprende un polipéptido aislado, el cual es un inhibidor de Nav1.7 restringido periféricamente. En algunas realizaciones que se dan a conocer, el polipéptido aislado es un inhibidor de Nav1.7 y/o Nav1.3. Otras realizaciones son realizaciones conjugadas de la composición y composiciones farmacéuticas. Se dan a conocer ácidos nucleicos aislados que codifican algunas realizaciones de polipéptidos y vectores de expresión, así como células huésped recombinantes que los contienen. También se da a conocer un método para tratar o prevenir el dolor. Reivindicación 1: Una composición de la materia, la cual comprende un polipéptido aislado que comprende la secuencia de aminoácidos de fórmula: Xₐₐ¹Xₐₐ²Xₐₐ³Xₐₐ⁴Xₐₐ⁵Xₐₐ⁶Xₐₐ⁷Xₐₐ⁸Xₐₐ⁹Xₐₐ¹⁰Xₐₐ¹¹Xₐₐ¹²Xₐₐ¹³Xₐₐ¹⁴Asp¹⁵Xₐₐ¹⁶Xₐₐ¹⁷Xₐₐ¹⁸Xₐₐ¹⁹Xₐₐ²⁰Xₐₐ²¹Xₐₐ²²Xₐₐ²³Xₐₐ²⁴Xₐₐ²⁵Xₐₐ²⁶Xₐₐ²⁷Xₐₐ²⁸Xₐₐ²⁹Xₐₐ³⁰Xₐₐ³¹Lys³²Xₐₐ³³Xₐₐ³⁴Xₐₐ³⁵Xₐₐ³⁶Xₐₐ³⁷Xₐₐ³⁸ // SEQ ID Nº 475 o una sal farmacéuticamente aceptable del mismo, en donde: Xₐₐ¹Xₐₐ² está ausente; o Xₐₐ¹ es un residuo aminoácido y Xₐₐ² es un residuo aminoácido; o Xₐₐ¹ está ausente y Xₐₐ² es un residuo aminoácido; Xₐₐ³ es Cys, si Xₐₐ¹⁸ es Cys; o Xₐₐ³ es SeCys, si Xₐₐ¹⁸ es SeCys; o Xₐₐ³ es un residuo alquil aminoácido, si Xₐₐ¹⁸ es un residuo aminoácido alquílico; Xₐₐ⁴ es un residuo aminoácido ácido, hidrofóbico, básico, o neutro hidrofílico; Xₐₐ⁵ es un residuo aminoácido Gly, Ala, hidrofóbico o básico; Xₐₐ⁶ es un residuo aminoácido Gly, Ala, 2-Abu, Nle, Nva, o hidrofóbico; Xₐₐ⁷ es un residuo aminoácido Gly, Ala, aromático o hidrofóbico; Xₐₐ⁸ es un residuo aminoácido básico, ácido, o neutro hidrofílico, o un residuo Ala; Xₐₐ⁹ es un residuo aminoácido hidrofílico básico o neutro; Xₐₐ¹⁰ es Cys si Xₐₐ²⁴ es Cys; o Xₐₐ¹⁰ es SeCys si Xₐₐ²⁴ es SeCys; Xₐₐ¹¹ es cualquier residuo aminoácido; Xₐₐ¹² es un residuo aminoácido Pro, ácido, neutro o hidrofóbico; Xₐₐ¹³ es cualquier residuo aminoácido; Xₐₐ¹⁴ es cualquier residuo aminoácido; Xₐₐ¹⁶ es un residuo aminoácido básico, neutro hidrofílico, o ácido, o un residuo Ala; Xₐₐ¹⁷ es Cys si Xₐₐ³¹ es Cys; o Xₐₐ¹⁷ es SeCys si Xₐₐ³¹ es SeCys; Xₐₐ¹⁸ es Cys, SeCys, o un residuo aminoácido alquílico; Xₐₐ¹⁹ es cualquier residuo aminoácido; Xₐₐ²⁰ es un Pro, Gly, o un residuo básico, o neutro hidrofílico; Xₐₐ²¹ es un residuo aminoácido básico, hidrofóbico, o neutro hidrofílico; Xₐₐ²² es un residuo aminoácido hidrofóbico o básico; Xₐₐ²³ es un residuo aminoácido hidrofóbico, básico o neutro hidrofílico; Xₐₐ²⁴ es un residuo Cys o SeCys; Xₐₐ²⁵ es un residuo aminoácido Ser, Ala, o neutro hidrofílico; Xₐₐ²⁶ es un residuo aminoácido Ala, ácido, básico o neutro hidrofílico; Xₐₐ²⁷ es un residuo ácido, básico, neutro hidrofílico o hidrofóbico; Xₐₐ²⁸ es un residuo aminoácido aromático o básico; Xₐₐ²⁹ es un residuo aminoácido ácido, básico, o neutro hidrofílico; Xₐₐ³⁰ es un residuo Trp, 5-bromoTrp, 6-bromoTrp, 5-cloroTrp, 6-cloroTrp, 1-Nal, 2-Nal, o tioTrp; Xₐₐ³¹ es Cys o SeCys; Xₐₐ³³ es un residuo aminoácido hidrofóbico o aromático; Xₐₐ³⁴ es cualquier residuo aminoácido; Xₐₐ³⁵ es un residuo aminoácido hidrofóbico; cada uno de Xₐₐ³⁶, Xₐₐ³⁷, y Xₐₐ³⁸ está ausente independientemente o es independientemente un residuo aminoácido neutro, básico o hidrofóbico; en donde: si Xₐₐ³ y Xₐₐ¹⁸ son ambos residuos Cys, existe un enlace disulfuro entre el residuo Xₐₐ³ y el residuo Xₐₐ¹⁸; o si Xₐₐ³ y Xₐₐ¹⁸ son ambos residuos SeCys, existe un enlace diseleniuro entre el residuo Xₐₐ³ y el residuo Xₐₐ¹⁸; si Xₐₐ¹⁰ y Xₐₐ²⁴ son ambos residuos Cys, existe un enlace disulfuro entre el residuo Xₐₐ¹⁰ y el residuo Xₐₐ²⁴; o si Xₐₐ¹⁰ y Xₐₐ²⁴ son ambos residuos SeCys, existe un enlace diseleniuro entre el residuo Xₐₐ¹⁰ y el residuo Xₐₐ²⁴; si Xₐₐ¹⁷ y Xₐₐ³¹ son ambos residuos Cys, existe un enlace disulfuro entre el residuo Xₐₐ¹⁷ y el residuo Xₐₐ³¹; o si Xₐₐ¹⁷ y Xₐₐ³¹ son ambos residuos SeCys, existe un enlace diseleniuro entre el residuo Xₐₐ¹⁷ y el residuo Xₐₐ³¹; el residuo amino terminal está opcionalmente acetilado, biotinilado o 4-pentinoilado, o PEGilado; y el residuo carboxi terminal está opcionalmente amidado.
ARP120100896A 2011-03-16 2012-03-19 INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7 AR088413A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453492P 2011-03-16 2011-03-16
US201261608088P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
AR088413A1 true AR088413A1 (es) 2014-06-11

Family

ID=45895479

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100896A AR088413A1 (es) 2011-03-16 2012-03-19 INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7

Country Status (24)

Country Link
US (2) US9340590B2 (es)
EP (1) EP2686340A2 (es)
JP (2) JP2014509859A (es)
KR (1) KR20140145947A (es)
CN (1) CN103930437A (es)
AP (1) AP2013007173A0 (es)
AR (1) AR088413A1 (es)
AU (1) AU2012228990B2 (es)
BR (1) BR112013023674A2 (es)
CA (1) CA2830065A1 (es)
CL (1) CL2013002673A1 (es)
CO (1) CO6821886A2 (es)
CR (1) CR20130533A (es)
EA (1) EA201391331A1 (es)
HK (1) HK1198173A1 (es)
MA (1) MA35385B1 (es)
MX (1) MX2013010497A (es)
PE (1) PE20140593A1 (es)
PH (1) PH12013501865A1 (es)
SG (2) SG10201601789TA (es)
TW (1) TW201300407A (es)
UY (1) UY33959A (es)
WO (1) WO2012125973A2 (es)
ZA (1) ZA201306920B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
EP3611180B1 (en) * 2013-03-15 2021-12-22 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage
SG10201807877TA (en) 2014-03-14 2018-10-30 Daniel Capon Hybrid immunoglobulin containing non-peptidyl linkage
BR122021025449B1 (pt) * 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
CN105348392B (zh) * 2015-11-18 2019-08-02 北京华金瑞清生物医药技术有限公司 一种Nav1.7抑制剂及其改造方法
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
KR102443631B1 (ko) * 2016-09-16 2022-09-15 올리패스 주식회사 Scn9a 안티센스 올리고뉴클레오티드
EP3573998A4 (en) * 2017-01-24 2020-12-16 Olipass Corporation SCN9A ANTISENSE PAIN RELIEF
CN109517041B (zh) * 2018-11-14 2019-09-17 青海芬陀利华生物科技有限公司 Gptx-1毒素及其应用
WO2021119157A1 (en) 2019-12-11 2021-06-17 Duke University Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same
AU2021320360B2 (en) * 2020-08-05 2025-07-10 National Institute Of Advanced Industrial Science And Technology Method for screening for polypeptide that acts on target protein
US20230374084A1 (en) 2020-09-23 2023-11-23 Aldevron, Llc Potent and selective inhibitors of nav1.7
CN113429463B (zh) * 2021-05-18 2022-08-23 湖南百尔泰克生物医药有限公司 一种具有镇痛作用的多肽及其应用
CN114805491B (zh) * 2022-03-15 2025-10-03 青岛海洋生物医药研究院 一种芋螺毒素kiiia突变体及其制备方法和应用
CN114805492B (zh) * 2022-03-15 2025-07-22 上海元炘执药科技有限公司 一种用于抑制电压门控钠离子通道1.4的芋螺毒素kiiia突变体及其制备方法和应用
CA3256604A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
CN114917324B (zh) * 2022-04-22 2025-05-30 江苏好上医生物医药有限公司 一种含虎纹毒素-iv的药物组合物及其应用
IL316462A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2026501116A (ja) 2022-12-06 2026-01-14 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のための製造方法
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025104668A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Anti-gastric inhibitory polypeptide receptor (gipr) antibodies and antibody conjugates for the treatment of metabolic disorders
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
TR2024005209A2 (tr) * 2024-04-30 2024-05-21 Vsy Bi̇yoteknoloji̇ Ve İlaç Sanayi̇ Anoni̇m Şi̇rketi̇ Bi̇lhassa i̇ntersti̇syel si̇sti̇t hastaliğinin tedavi̇si̇ i̇çi̇n bi̇r formülasyon
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4083368A (en) 1976-09-01 1978-04-11 Freezer Winthrop J Inhaler
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
ATE135045T1 (de) 1988-07-23 1996-03-15 Delta Biotechnology Ltd Sekretorische leader-sequenzen
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
DE69233069T2 (de) 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
JPH0640945A (ja) 1992-07-23 1994-02-15 Kureha Chem Ind Co Ltd Ｆｃフラグメント結合抗腫瘍剤
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5432155A (en) 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
US5514774A (en) 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1995022992A2 (en) 1994-02-23 1995-08-31 Chiron Corp Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996019205A1 (en) 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
ATE236617T1 (de) 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5756663A (en) 1996-01-03 1998-05-26 Zeneca Limited Antiarrhythmic peptide from venom of spider Grammostola spatulata
US5776896A (en) 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
AU5369798A (en) 1996-11-27 1998-06-22 Bachem Bioscience, Inc. Shk toxin compositions and methods of use
EP0916681B1 (en) 1996-12-26 2005-10-26 Suntory Limited Neuropeptides originating in scorpion
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP3530004B2 (ja) 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE69940785D1 (de) 1998-11-20 2009-06-04 Fuso Pharmaceutical Ind Proteinexpressionsvektor und benutzung desselbigen
ATE251448T1 (de) 1998-12-23 2003-10-15 Amgen Inc Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
JP2002538841A (ja) 1999-03-18 2002-11-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２７個のヒト分泌タンパク質
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE1252330T1 (de) 1999-11-26 2003-11-27 Mcgill University, Montreal Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie
WO2001055317A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
SE0000935D0 (sv) 2000-03-21 2000-03-21 Astrazeneca Ab An inhalation device
US7125847B1 (en) 2000-04-07 2006-10-24 The Research Foundation Of State University Of New York At Buffalo Mechanically activated channel blocker
CN1133461C (zh) 2000-04-11 2004-01-07 厦门北大之路生物工程有限公司 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用
ATE301190T1 (de) 2000-05-10 2005-08-15 Centre Nat Rech Scient Protonen-abhängiges na+kanal hemmendes polypeptid
EP1177806A1 (en) 2000-08-04 2002-02-06 The Technology Partnership Public Limited Company Dry powder inhaler
GB0021617D0 (en) 2000-09-02 2000-10-18 Imp College Innovations Ltd Diagnosis and treatment of cancer
JP5013152B2 (ja) 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
ATE527375T1 (de) 2001-04-12 2011-10-15 Imp Innovations Ltd Diagnose und behandlung von brustkrebs mit scn5a
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
ES2561108T3 (es) 2001-10-19 2016-02-24 Idexx Laboratories, Inc. Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
WO2003072751A2 (en) 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
WO2004085647A1 (ja) 2003-03-26 2004-10-07 Pharmadesign, Inc. イオンチャネルの活性を阻害する低分子ペプチド
US20070253966A1 (en) 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
JP4808156B2 (ja) 2003-08-05 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
NZ545710A (en) 2003-08-08 2010-02-26 Vertex Pharma Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US7670771B2 (en) 2004-01-21 2010-03-02 University Of Utah Research Foundation Mutant sodium channel Nav1.7 nucleic acid methods
WO2005118614A1 (en) 2004-04-08 2005-12-15 Avigen, Inc. Methods and compositions for treating neuropathic pain
US7323169B2 (en) 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations
WO2006000116A1 (de) 2004-06-23 2006-01-05 Huber+Suhner Ag Breitband-patchantenne
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
WO2006014493A2 (en) * 2004-07-07 2006-02-09 The Research Foundation Of State University Of New York Stor Mechanically activated channel blocker
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
MX2007004074A (es) 2004-10-07 2007-08-14 Univ California Analogos de toxina shk y sus usos en inhibicion selectiva de canales de potasio kv1.3.
US7767680B2 (en) 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US20060199812A1 (en) 2005-01-24 2006-09-07 Amgen Inc. Method of conjugating aminothiol containing molecules to vehicles
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
GB0517487D0 (en) 2005-08-26 2005-10-05 Isis Innovation Antibodies
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
EP1948685B1 (en) 2005-11-08 2018-04-18 Activen Sa Mu-conotoxin peptides and use thereof as a local anesthetic
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
EP2628749A3 (en) 2006-06-20 2013-12-04 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Antimicrobial kinocidin compostions and methods of use
JP4742345B2 (ja) * 2006-06-20 2011-08-10 独立行政法人産業技術総合研究所 カルシウムチャネルを遮断するグラモストラ・スパチュラタ由来のポリペプチドおよびその遺伝子
US7820623B2 (en) * 2006-10-25 2010-10-26 Amgen Inc. Conjugated toxin peptide therapeutic agents
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
CN101480393A (zh) * 2008-01-07 2009-07-15 云南昊邦制药有限公司 草乌甲素作为制备治疗Nav1.7疼痛病症药物的应用
WO2009097530A2 (en) 2008-01-30 2009-08-06 Baylor College Of Medicine Peptides that target dorsal root ganglion neurons
CA2751159A1 (en) 2009-02-02 2010-08-05 Chromocell Corporation Cell lines expressing nav and methods of using them
WO2010104114A1 (ja) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 ポリペプチドライブラリーを調製する方法
WO2010104115A1 (ja) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 膜タンパク質を特異的に認識するポリペプチドの調製方法
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
BR112012005860A2 (pt) 2009-09-15 2017-01-31 Alomone Preclinical Ltd peptídeos isolados do veneno de aranha, e usos dos mesmos
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
EP2493926B1 (en) 2009-10-27 2020-03-11 UCB Biopharma SRL Function modifying nav 1.7 antibodies
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
US9279003B2 (en) 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
AU2013262630B2 (en) 2012-05-18 2017-11-16 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use

Also Published As

Publication number Publication date
CO6821886A2 (es) 2013-12-31
PH12013501865A1 (en) 2014-01-06
CR20130533A (es) 2014-01-09
WO2012125973A2 (en) 2012-09-20
NZ615242A (en) 2016-03-31
US20160304570A1 (en) 2016-10-20
JP2017031157A (ja) 2017-02-09
AU2012228990A1 (en) 2013-09-19
HK1198173A1 (en) 2015-03-13
JP2014509859A (ja) 2014-04-24
UY33959A (es) 2012-09-28
SG193434A1 (en) 2013-10-30
US20140073577A1 (en) 2014-03-13
AP2013007173A0 (en) 2013-10-31
AU2012228990B2 (en) 2017-04-06
CL2013002673A1 (es) 2014-07-25
US9796766B2 (en) 2017-10-24
US9340590B2 (en) 2016-05-17
MA35385B1 (fr) 2014-09-01
ZA201306920B (en) 2014-05-28
EA201391331A1 (ru) 2014-02-28
KR20140145947A (ko) 2014-12-24
CN103930437A (zh) 2014-07-16
WO2012125973A3 (en) 2013-01-03
CA2830065A1 (en) 2012-09-20
SG10201601789TA (en) 2016-04-28
EP2686340A2 (en) 2014-01-22
TW201300407A (zh) 2013-01-01
MX2013010497A (es) 2013-12-16
BR112013023674A2 (pt) 2016-12-13
PE20140593A1 (es) 2014-05-10

Similar Documents

Publication Publication Date Title
AR088413A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
FI3642340T3 (fi) Muunneltu l-asparaginaasi
JP2013518115A5 (es)
ES2574082T3 (es) Proteínas que encapsulan aceites modificados y usos de los mismos
RU2017118326A (ru) Бициклические пептидные лиганды, специфичные для мт1-ммр
JP2012530145A5 (es)
NZ597306A (en) Mesenchymal stem cell differentiation
PE20091067A1 (es) Variantes de peptidos natriureticos de tipo c
AU2017261479B2 (en) Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28
CN107249616A (zh) 芋螺毒素(conotoxin)肽的修饰和用途
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
FI3712264T3 (fi) Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon
WO2020086580A1 (en) Therapeutic combinations of tdfrps and additional agents and methods of use
RU2013113724A (ru) Способ очистки пегилированного эритропоэтина
MX2022007546A (es) Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
NZ707895A (en) Formulation for bispecific t-cell engagers (bites)
KR102093093B1 (ko) 피부 노화 개선용 조성물
CN116888146A (zh) 胰高血糖素样肽-1受体拮抗剂
KR20110091720A (ko) Ｃｒｈｒ2 펩티드 작용제 및 이의 용도
CA2581110A1 (en) Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
WO2016151478A1 (en) Stapled peptides and uses thereof
CA2719940A1 (en) Methods for treating acute myocardial infarction
US10947274B1 (en) Synthetic analgesic peptides of RgIA analogs

Legal Events

Date Code Title Description
FB Suspension of granting procedure